These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22423124)

  • 1. Poorer immunologic outcome on treatment among patients infected with HIV-1 non-B subtypes compared with subtype B in Singapore.
    Lee LK; Lin L; Chua A; Leo YS; Ng OT
    Clin Infect Dis; 2012 Jun; 54(12):1818-20. PubMed ID: 22423124
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
    Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
    Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.
    Li T; Wu N; Dai Y; Qiu Z; Han Y; Xie J; Zhu T; Li Y
    Clin Infect Dis; 2011 Nov; 53(9):944-51. PubMed ID: 21960716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
    Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy.
    Franzetti M; Violin M; Casazza G; Meini G; Callegaro A; Corsi P; Maggiolo F; Pignataro AR; Paolucci S; Gianotti N; Francisci D; Rossotti R; Filice G; Carli T; Zazzi M; Balotta C
    Clin Microbiol Infect; 2012 Mar; 18(3):E66-70. PubMed ID: 22192680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
    Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
    J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.
    Fontas E; Kousignian I; Pradier C; Poizot-Martin I; Durier C; Weiss L; Levy Y; Costagliola D; ;
    J Antimicrob Chemother; 2010 Oct; 65(10):2215-23. PubMed ID: 20702463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short communication: HIV type 1 subtype BF leads to faster CD4+ T cell loss compared to subtype B.
    Tarosso LF; Sanabani SS; Ribeiro SP; Sauer MM; Tomiyama HI; Sucupira MC; Diaz RS; Sabino EC; Kalil J; Kallas EG
    AIDS Res Hum Retroviruses; 2014 Feb; 30(2):190-4. PubMed ID: 23906381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy.
    Nicastri E; Dori L; Buonomini AR; Tommasi C; De Nardo P; Bellagamba R; Corpolongo A; Montano M; Sordillo P; Volpi A; Sarmati L; Andreoni M
    AIDS; 2012 Jul; 26(11):1451-2. PubMed ID: 22767346
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of HIV-1 non-B subtype infections in Northwest Poland.
    Parczewski M; Leszczyszyn-Pynka M; Bander D; Urbańska A; Stańczak G; Boroń-Kaczmarska A
    J Med Virol; 2010 Aug; 82(8):1306-13. PubMed ID: 20578066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
    Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
    Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 dual infection is associated with faster CD4+ T-cell decline in a cohort of men with primary HIV infection.
    Cornelissen M; Pasternak AO; Grijsen ML; Zorgdrager F; Bakker M; Blom P; Prins JM; Jurriaans S; van der Kuyl AC
    Clin Infect Dis; 2012 Feb; 54(4):539-47. PubMed ID: 22157174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CD4 T cell count on the outcome of planned treatment interruptions in early-treated human immunodeficiency virus-infected children.
    Fortuny C; Noguera-Julian A; Alsina L; Bellido R; Sánchez E; Muñoz-Almagro C; Ruiz L; Jiménez R
    Pediatr Infect Dis J; 2011 May; 30(5):435-8. PubMed ID: 21030884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
    Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
    J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
    Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
    J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
    Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
    AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
    Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
    J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.